Last reviewed · How we verify
Isobaric Bupivacaine
Isobaric Bupivacaine, marketed by Diskapi Yildirim Beyazit Education and Research Hospital, is a local anesthetic currently available in the market. The key composition patent for Isobaric Bupivacaine is set to expire in 2028, which may provide a period of market exclusivity and competitive advantage. However, the lack of specified primary indication and revenue data poses a significant risk in assessing its market performance and potential threats from competitors.
At a glance
| Generic name | Isobaric Bupivacaine |
|---|---|
| Also known as | Marcain flakon |
| Sponsor | Diskapi Yildirim Beyazit Education and Research Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Retrolaminar Block Versus Subcostal Transversus Abdominis Plane Block in Liver Resection Surgery (NA)
- The Effect of Epidural Anesthesia on Optic Nerve Sheath Diameter Measurements in Total Knee Prosthesis Surgery (NA)
- Comparison of Lumbar Erector Spinae Plane Block and Spinal Anesthesia in Hip and Proximal Femur Surgery (NA)
- Vaginal Cuff Bupivacaine Injection for Postoperative Pain (NA)
- Comparison of Hypotension After Spinal Anesthesia With Hyperbaric Vs Isobaric Bupivacaine in Elective Cesarean After Colloid Preloading. (PHASE2)
- Maxillary and Mandibular Nerve Block (NA)
- Caudal Dexmedetomidine vs Ketamine for Postoperative Analgesia in Pediatric DDH Surgery (NA)
- Analgesia After Video-Assisted Thoracic Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |